ProKidney Corp
PROK
Company Profile
Business description
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Contact
2000 Frontis Plaza Boulevard
Suite 250
Winston-SalemNC27103
USAT: +1 336 999-7019
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
231
Stocks News & Analysis
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,975.10 | 30.50 | -0.34% |
| CAC 40 | 8,385.49 | 44.78 | 0.54% |
| DAX 40 | 24,740.36 | 153.22 | -0.62% |
| Dow JONES (US) | 51,848.90 | 182.06 | 0.35% |
| FTSE 100 | 10,461.63 | 32.78 | 0.31% |
| HKSE | 23,114.79 | 297.39 | -1.27% |
| NASDAQ | 25,476.64 | 110.40 | -0.43% |
| Nikkei 225 | 71,854.88 | 2,679.91 | 3.87% |
| NZX 50 Index | 13,494.22 | 93.56 | 0.70% |
| S&P 500 | 7,358.22 | 7.24 | -0.10% |
| S&P/ASX 200 | 8,775.10 | 25.50 | -0.29% |
| SSE Composite Index | 4,112.47 | 1.65 | 0.04% |